The Adrenocortical Carcinoma (Adrenal Cortex Cancer) drugs in development market research report provides comprehensive information on the therapeutics under development for Adrenocortical Carcinoma (Adrenal Cortex Cancer), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Adrenocortical Carcinoma (Adrenal Cortex Cancer). Buy the report here.
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Adrenocortical Carcinoma (Adrenal Cortex Cancer) and features dormant and discontinued products.
GlobalData tracks 23 drugs in development for Adrenocortical Carcinoma (Adrenal Cortex Cancer) by 21 companies/universities/institutes. The top development phase for Adrenocortical Carcinoma (Adrenal Cortex Cancer) is phase i with ten drugs in that stage. The Adrenocortical Carcinoma (Adrenal Cortex Cancer) pipeline has 20 drugs in development by companies and three by universities/ institutes. Some of the companies in the Adrenocortical Carcinoma (Adrenal Cortex Cancer) pipeline products market are: Pharma Mar, Eisai and Shanghai Jiao Tong University School of Medicine.
The key targets in the Adrenocortical Carcinoma (Adrenal Cortex Cancer) pipeline products market include Vascular Endothelial Growth Factor Receptor 2 (Fetal Liver Kinase 1 or Kinase Insert Domain Receptor or Protein Tyrosine Kinase Receptor flk 1 or VEGFR2 or CD309 or KDR or EC 2.7.10.1), Vascular Endothelial Growth Factor Receptor 1 (Fms Like Tyrosine Kinase 1 or Tyrosine Protein Kinase Receptor FLT or Tyrosine Protein Kinase FRT or Vascular Permeability Factor Receptor or VEGFR1 or FLT1 or EC 2.7.10.1), and Vascular Endothelial Growth Factor Receptor 3 (Fms Like Tyrosine Kinase 4 or Tyrosine Protein Kinase Receptor FLT4 or VEGFR3 or FLT4 or EC 2.7.10.1).
The key mechanisms of action in the Adrenocortical Carcinoma (Adrenal Cortex Cancer) pipeline product include Proto Oncogene Tyrosine Protein Kinase Receptor Ret (Cadherin Family Member 12 or Proto Oncogene c Ret or RET or EC 2.7.10.1) Inhibitor with two drugs in Phase II. The Adrenocortical Carcinoma (Adrenal Cortex Cancer) pipeline products include ten routes of administration with the top ROA being Intravenous and seven key molecule types in the Adrenocortical Carcinoma (Adrenal Cortex Cancer) pipeline products market including Small Molecule, and Monoclonal Antibody.
Adrenocortical Carcinoma (Adrenal Cortex Cancer) overview
Adrenal cortex cancer (ACC) is a rare disease. It is caused by a cancerous growth in the adrenal cortex, which is the outer layer of the adrenal glands. Predisposing factors include female sex, hereditary disease that affects the adrenal glands, age, and smoking. Symptoms include high blood sugar and pressure, muscle weakness in the legs, excessive weight gain in the chest and abdomen, early signs of puberty in children, and increased facial and body hair (particularly in females) and deepened voice in females.
For a complete picture of Adrenocortical Carcinoma (Adrenal Cortex Cancer)’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
